ArticleJournal of cancer survivorship : research and practice2008
Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors.
Article in Journal of cancer survivorship : research and practice, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Therapy of clinical stage IIA and IIB seminoma: a systematic review.World journal of urology · 2022Pooled it
- [Follow-up of testicular germ cell cancer patients: interdisciplinary evidence-based recommendations].Der Urologe. Ausg. A · 2011Guideline
- Risk of osteoporosis in testicular germ cell tumour survivors: A systematic review of the literature.BJUI compass · 2023Review
- Vascular toxic effects of cancer therapies.Nature reviews. Cardiology · 2020Review
- Cisplatin treatment of testicular cancer patients introduces long-term changes in the epigenome.Clinical epigenetics · 2019Article
- Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score.Clinical genitourinary cancer · 2018Article
- Erratum to: Dendritic cells as therapeutic targets in neuroinflammation.Cellular and molecular life sciences : CMLS · 2016Article
- [Follow-up of urological tumor treatment].Der Urologe. Ausg. A · 2015Review
- Effects of cisplatin on the contractile function of thoracic aorta of Sprague-Dawley rats.Biomedical reports · 2014Article
- Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors.British journal of cancer · 2013Article
- Pure seminoma: a review and update.Radiation oncology (London, England) · 2011Review
- Interdisciplinary evidence-based recommendations for the follow-up of early stage seminomatous testicular germ cell cancer patients.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2011Article
- A controlled study of risk factors for disease and current problems in long-term testicular cancer survivors.Journal of cancer survivorship : research and practice · 2010Article
- Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors.Journal of the National Cancer Institute · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe examined if testicular cancer (TC) treatment is associated with any risk for cardiovascular morbidity or predicted mortality according to the SCORE model, in which a 10-year future risk of >or=5% for developing a fatal cardiovascular event qualify for high-risk status.
methodsOne thousand one hundred thirty-four TC survivors treated 1980-1994 participated in this study (1998-2002). Patients were categorised in four treatment groups: surgery (n = 225), radiotherapy (n = 445), and two chemotherapy groups: cumulative cisplatin dose <or=850 mg (n = 375) and >850 mg (cis>850, n = 89). Patients with cardiovascular disease, diabetes or SCORE >or=5% constituted a high-risk group, and those with SCORE >1% an intermediate/high risk group.
resultsAge-adjusted mean SCORE was 0.93% for the surgery group. In comparison, chemotherapy treated patients had significantly higher SCORE (1.07%, p = 0.01). Only 15% of patients were scored to be at high-risk, while 53% qualified for the intermediate/high risk group. Patients in the cis>850 group had increased odds for having intermediate/high risk, compared with the surgery group (OR 3.4, 95% CI 1.3-8.7). Only 23 cardiovascular events had occurred since the testicular cancer diagnosis.
conclusionThe SCORE model indicates that patients treated with cisplatin-based chemotherapy have a significantly increased future risk of a fatal cardiovascular event. IMPLICATIONS FOR CANCER SURVIVORS: TC survivors should be followed regularly with respect to cardiovascular risk profile beyond the routine 10-year clinical follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.